Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Welcome,         Profile    Billing    Logout  
 6 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mngqibisa, Rosie
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT05630872: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

Active, not recruiting
2
30
RoW
Dolutegravir (DTG) 50 mg orally BID (~12 hours apart) plus TDF/3TC, DTG 50 mg orally QD plus TDF/3TC, 2HPZM, 2HPM
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare, Mylan Inc.
HIV-associated Tuberculosis
02/25
09/25
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection

Recruiting
2
150
Europe, Canada, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline
Hepatitis B
01/27
05/27
HVTN605A5421, NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa

Recruiting
2
276
RoW
MTBVAC, BCG
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Biofabri, S.L
HIV I Infection, Tuberculosis
02/26
02/26
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Not yet recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
03/25
03/26
NCT05383742: Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Recruiting
2
330
RoW
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
05/27
05/27
B-Sure, NCT04954859 / 2021-000554-26: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

Recruiting
2
450
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Hepatitis B
02/29
02/29
NCT06702449: A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

Recruiting
1/2
448
Europe, US, RoW
Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
GlaxoSmithKline
Urinary Tract Infections
08/27
08/27
Reyneke, Anne
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
HVTN605A5421, NCT05947890: Evaluating the Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living With and Without HIV in South Africa

Recruiting
2
276
RoW
MTBVAC, BCG
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), Biofabri, S.L
HIV I Infection, Tuberculosis
02/26
02/26
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
03/25
03/26

Download Options